Global medical technology business, Smith+Nephew, founded in 1856, is set to build a new £80 million production and R&D facility near Hull.

Smith+Nephew has appointed Race Cottam Associates (RCA) to design its new £80 million production and R&D facility in Melton – one of the largest investments in the British medical equipment manufacturer’s 166-year history.

The historic company which was founded in Hull in 1856, confirmed it would be relocating to a 25-acre site at Melton West Business Park, approximately eight miles from their current site at Daltry Street. The firm will invest more than £80 million building the new facility, which will create a world class R&D, manufacturing and flexible office environment. RCA has been appointed as full project architect, following a competitive tender process.

The development will also be supported by a grant from UK Government and is expected to support more than $10 billion of sales in its first ten years of operation.  

Simon Fraser, President of Advanced Wound Management, Smith+Nephew, said:

“This major investment demonstrates our commitment to the UK and to building our leadership in Advanced Wound Management. Our vision is for a world-class working environment that encourages innovation and collaboration to deliver next-generation products that improve the standard of care for the NHS and customers around the world. Smith+Nephew was founded in Hull in 1856 and we are proud to make this major investment in the region for future generations.”

Lord Grimstone, Minister for Investment, said:

“As set out in our Life Sciences Vision, we are committed to harnessing our skilled workforce and existing strengths in R&D to continue to attract large scale manufacturing and the economic opportunities that come with them. Today’s announcement from Smith+Nephew is a major vote of confidence in our thriving Life Sciences sector, cementing the UK’s status as a global science superpower and helping us to level up economic growth across the country.”

Lord Kamall, Minister for Innovation, said:

“Life sciences are crucial to transforming our health service and ensure the NHS is able to deliver world-class care. Coupled with health research, it has been vital in our fight against Covid and in saving thousands of lives through the rapid creation of vaccines and identifying life-saving treatments like dexamethasone.  Smith+Nephew’s new R&D base will ensure the UK remains at the forefront of life sciences and innovative research, levelling up the health of our nation, tackling disparities and saving lives.”

The vision for the circa 30,000m² new building is to create a world-class working environment capable of delivering next generation products that will improve the standard of care for the NHS and customers across the globe. It will encourage innovation and collaboration, accommodate key manufacturing spaces and advanced laboratories which meet stringent cleanliness standards, and be future proof in terms of flexibility of space.

The new site is expected to open in 2024. 

LEAVE A REPLY

Please enter your comment!
Please enter your name here